CureVac (Germany)

Recent papers from CureVac (Germany)

1. An mRNA-based FimH nanoparticle vaccine against uropathogenic Escherichia coli confers protection in a mouse model of recurrent urinary tract infectionFrontiers in Immunology · 2026
2. Safety and immunogenicity of an mRNA COVID-19 vaccine administered to adults: A phase 2, randomized, active-controlled trialHuman Vaccines & Immunotherapeutics · 2026
3. Safety and immunogenicity of an investigational mRNA-lipid nanoparticle-based monovalent influenza vaccine: Results from a phase 1, randomized, dose-escalation studySHILAP Revista de lepidopterología · 2026
4. Boosting SIV-specific CD8+ T cell responses prior to ART interruption extends time to SIVmac239 reboundJournal of Clinical Investigation · 2026
5. An mRNA-based FimH nanoparticle vaccine against uropathogenic Escherichia coli is highly immunogenic in rodentsFrontiers in Immunology · 2025
6. Impact of the COVID-19 pandemic on the routine immunization system in BangladeshPLoS ONE · 2025
7. Preclinical development of an mRNA-based multiepitope immunotherapeutic for glioblastomaCancer Immunology Immunotherapy · 2025
8. NANOSPRESSO: toward personalized, locally produced nucleic acid nanomedicinesFrontiers in Science · 2025
9. Rapid and Accurate Quantification of RNA in Lipid Nanoparticles by Scatter-Free UV/Visible SpectroscopyNano Letters · 2025
10. Phase I study of intratumoral administration of CV8102 in patients with advanced melanoma, squamous cell carcinoma of the skin, squamous cell carcinoma of the head and neck, or adenoid cystic carcinomaJournal for ImmunoTherapy of Cancer · 2025
11. Safety and immunogenicity of a bivalent norovirus vaccine candidate in infants from 6 weeks to 5 months of age: A phase 2, randomized, double-blind trialHuman Vaccines & Immunotherapeutics · 2025
12. An mRNA-encoded dominant-negative inhibitor of transcription factor RUNX1 suppresses vitreoretinal disease in experimental modelsScience Translational Medicine · 2024
13. What’s in a word? Defining “gene therapy medicines”Molecular Therapy — Methods & Clinical Development · 2024
14. Safety and immunogenicity of a modified mRNA-lipid nanoparticle vaccine candidate against COVID-19: Results from a phase 1, dose-escalation studyHuman Vaccines & Immunotherapeutics · 2024
15. mRNA vaccine-induced IgG mediates nasal SARS-CoV-2 clearance in miceMolecular Therapy — Nucleic Acids · 2024
16. A First-in-Human Study of cinrebafusp alfa, a HER2/4-1BB Bispecific Molecule, in Patients with HER2-Positive Advanced Solid MalignanciesClinical Cancer Research · 2024
17. In Vivo PET Detection of Lung Micrometastasis in Mice by Targeting Endothelial VCAM-1 Using a Dual-Contrast PET/MRI ProbeInternational Journal of Molecular Sciences · 2024
18. A phase 3, randomised, observer-blinded, placebo controlled-trial evaluating the safety and immunogenicity of investigational SARS-CoV-2 mRNA vaccine CVnCoV in adult healthcare workers in Mainz (Germany)Vaccine X · 2024
19. Phase 1 dose-finding study to evaluate safety and tolerability of CVGBM in patients with newly diagnosed and surgically resected MGMT-unmethylated glioblastoma.Journal of Clinical Oncology · 2024
20. Quality Control of mRNA Vaccines by Synthetic Ribonucleases: Analysis of the Poly‐A‐TailChemBioChem · 2024